Carson Michael J.'s Form 4 filing
Nuvectis Pharma, Inc. (NVCT) · filed Nov 8, 2024
- Accession no.
- 0001104659-24-115837
- Filed
- Nov 8, 2024
- Trade date
- Jan 3, 2023-Nov 7, 2024
- Filing delay
- 675 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $22.5K. It was filed 675 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Carson Michael J.CIK 0001896079 | Officer (Vice President, Finance) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Common Stock | AGrant or awardAcquired | +28,806 | $0.00 | $0 | 56,106 | Direct | |
| Jan 4, 2024 | Common Stock | AGrant or awardAcquired | +34,567 | $0.00 | $0 | 90,673 | Direct | |
| Nov 7, 2024 | Common Stock | SSaleDisposed | −2,755 | $8.16 | −$22,480.8 | 87,918 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.